ACP puts hormone therapy first for menopause symptoms - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

ACP puts hormone therapy first for menopause symptoms

Estrogen-based therapy is now recommended first for vasomotor symptoms, with SNRIs, SSRIs, gabapentin, and neurokinin receptor antagonists reserved for later lines.

  • By

  • Teraya Smith

  • October 6, 2026

  • 4 min

Share

Clinical Report: ACP puts hormone therapy first for menopause symptoms

Overview

The American College of Physicians recommends hormone therapy as the first-line treatment for menopausal vasomotor symptoms, based on high-certainty evidence supporting the efficacy of estrogen alone or combined with progestogen.

Background

Menopausal vasomotor symptoms significantly impact quality of life for many women. The recent guidelines from the American College of Physicians provide a structured approach to treatment options.

Data Highlights

No numerical data provided in the source material.

Key Findings

  • The ACP recommends estrogen therapy as first-line treatment for menopausal vasomotor symptoms.
  • Estrogen combined with progestogen is advised for patients with a uterus, while estrogen alone is recommended for those without.
  • Second-line options include desvenlafaxine or venlafaxine for patients intolerant to estrogen therapy.
  • Gabapentin and neurokinin receptor antagonists are considered third-line treatments.
  • High-dose estrogen is more effective than low-dose for symptom reduction.
  • Evidence on the risks associated with different estrogen administration routes remains insufficient.

Clinical Implications

Clinicians should inquire about vasomotor symptoms directly. Treatment efficacy should be evaluated after 8 to 12 weeks.

Conclusion

The ACP's guidelines provide a framework for managing menopausal vasomotor symptoms.

Related Resources & Content

  1. American College of Physicians, Annals of Internal Medicine, 2026 -- ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms
  2. ASCO Publications — Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
  3. ASCO Publications — Advances in Adjuvant Hormonal Therapy for Postmenopausal Women
  4. Associated Press Health — A look at nonhormonal options for menopause symptoms
  5. ASCO Publications — Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy
  6. A look at nonhormonal options for menopause symptoms
  7. ACP recommends hormonal therapy as a first-line treatment for menopausal vasomotor symptoms | ACP Online
  8. https://healthquality.va.gov/HEALTHQUALITY/guidelines/WH/menopause/Menopause-CPG_2026-Guideline_v1_20260930.pdf
  9. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: A Phase 3 Randomized Clinical Trial - PubMed

Original Source(s)

ACP puts hormone therapy first for menopause symptoms

  • by Teraya Smith

  • October 6, 2026

Related Content

ACP Suggests First-Line Obesity Drugs

Semaglutide and tirzepatide had the greatest net benefit among evaluated treatments, the committee concluded.

Patient-Reported Symptoms in Climacteric Syndrome: Insights from a Network Analysis at a Single Center

Top 10 States With Rising Demand for Physicians

These 10 states report physician shortages, projected physician supply gaps, or physician-to-population ratios below national benchmarks.